SHARON PLON to Heterozygote
This is a "connection" page, showing publications SHARON PLON has written about Heterozygote.
Connection Strength
1.213
-
Improvement of outcomes for TP53 carriers. Lancet Oncol. 2016 09; 17(9):1184-6.
Score: 0.427
-
Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers. Breast Cancer Res Treat. 2011 Aug; 129(1):221-7.
Score: 0.295
-
Heterozygous screen in Saccharomyces cerevisiae identifies dosage-sensitive genes that affect chromosome stability. Genetics. 2008 Mar; 178(3):1193-207.
Score: 0.237
-
Parent decision-making around the genetic testing of children for germline TP53 mutations. Cancer. 2015 Jan 15; 121(2):286-93.
Score: 0.094
-
Cancer. A risky business--assessing breast cancer risk. Science. 2003 Oct 24; 302(5645):574-5.
Score: 0.044
-
Counseling the at risk patient in the BRCA1 and BRCA2 Era. Obstet Gynecol Clin North Am. 2002 Jun; 29(2):341-66, vii.
Score: 0.040
-
Mammography behavior after receiving a negative BRCA1 mutation test result in the Ashkenazim: a community-based study. Genet Med. 2000 Nov-Dec; 2(6):307-11.
Score: 0.036
-
PMS2 monoallelic mutation carriers: the known unknown. Genet Med. 2016 Jan; 18(1):13-9.
Score: 0.024
-
Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2010 Jul; 122(1):281-5.
Score: 0.017